These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
294 related articles for article (PubMed ID: 31802119)
1. Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo-β-Lactamase-1. Yasmin M; Fouts DE; Jacobs MR; Haydar H; Marshall SH; White R; D'Souza R; Lodise TP; Rhoads DD; Hujer AM; Rojas LJ; Hoyen C; Perez F; Edwards A; Bonomo RA Clin Infect Dis; 2020 Aug; 71(4):1095-1098. PubMed ID: 31802119 [TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755 [TBL] [Abstract][Full Text] [Related]
4. Outcomes of 23 patients diagnosed with New Delhi metallo-beta-lactamase (NDM)-producing Klebsiella pneumoniae infection treated with ceftazidime/avibactam and aztreonam at a single center in Poland. Guzek A; Rybicki Z; Tomaszewski D; Mackiewicz K; Piechota W; Chciałowski A Eur J Clin Microbiol Infect Dis; 2024 Aug; 43(8):1579-1587. PubMed ID: 38811482 [TBL] [Abstract][Full Text] [Related]
5. Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies. Xu C; Wei X; Jin Y; Bai F; Cheng Z; Chen S; Pan X; Wu W Microbiol Spectr; 2022 Oct; 10(5):e0139022. PubMed ID: 35972286 [TBL] [Abstract][Full Text] [Related]
6. Aztreonam plus ceftazidime-avibactam as treatment of NDM-1-producing Klebsiella pneumoniae bacteraemia in a neutropenic patient: Last resort therapy? Bocanegra-Ibarias P; Camacho-Ortiz A; Garza-González E; Flores-Treviño S; Kim H; Perez-Alba E J Glob Antimicrob Resist; 2020 Dec; 23():417-419. PubMed ID: 33212285 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Persistently Neutropenic Rabbits. Petraitiene R; Petraitis V; Kavaliauskas P; Maung BBW; Khan F; Naing E; Aung T; Zigmantaite V; Grigaleviciute R; Kucinskas A; Stakauskas R; Georgiades BN; Mazur CA; Hayden JA; Satlin MJ; Walsh TJ Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015048 [No Abstract] [Full Text] [Related]
8. Susceptibility evaluation of novel beta-lactam/beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in hospitalized patients in Brazil. Wilhelm CM; Antochevis LC; Magagnin CM; Arns B; Vieceli T; Pereira DC; Lutz L; de Souza ÂC; Dos Santos JN; Guerra RR; Medeiros GS; Santoro L; Falci DR; Rigatto MH; Barth AL; Martins AF; Zavascki AP J Glob Antimicrob Resist; 2024 Sep; 38():247-251. PubMed ID: 38936472 [TBL] [Abstract][Full Text] [Related]
9. Bloodstream infection by two subpopulations of Klebsiella pneumoniae ST1685 carrying KPC-33 or KPC-14 following ceftazidime/avibactam treatment: considerations regarding acquired heteroresistance and choice of carbapenemase detection assay. Bianco G; Boattini M; Iannaccone M; Cavallo R; Costa C J Antimicrob Chemother; 2020 Oct; 75(10):3075-3076. PubMed ID: 32676660 [No Abstract] [Full Text] [Related]
10. Effect of ceftazidime-avibactam combined with different antimicrobials against carbapenem-resistant Wu Y; Yu W; Chu X; Zhang J; Jia P; Liu X; Zhu Y; Xu Y; Yang Q Microbiol Spectr; 2024 Jun; 12(6):e0010724. PubMed ID: 38712934 [TBL] [Abstract][Full Text] [Related]
11. Ceftazidime-avibactam alone or in combination with Aztreonam versus Polymyxins in the management of carbapenem-Resistant Klebsiella pneumoniae nosocomial Infections (CAPRI study): a retrospective cohort study from South India. Sree RA; Gupta A; Gupta N; Veturi S; Reddy LSK; Begum M; Shravani E; Challa HR; Reddy SS; Singamsetty A; Arumilli M; Reddy PN; Tirlangi PK Infection; 2024 Apr; 52(2):429-437. PubMed ID: 37697224 [TBL] [Abstract][Full Text] [Related]
12. Evolution of Won EJ; Park K; Jeong YS; Kim J; Choi Y; Kim SH; Kim MN; Sung H J Korean Med Sci; 2024 Jul; 39(25):e208. PubMed ID: 38952349 [TBL] [Abstract][Full Text] [Related]
13. Impact of a Rapid Molecular Test for Klebsiella pneumoniae Carbapenemase and Ceftazidime-Avibactam Use on Outcomes After Bacteremia Caused by Carbapenem-Resistant Enterobacterales. Satlin MJ; Chen L; Gomez-Simmonds A; Marino J; Weston G; Bhowmick T; Seo SK; Sperber SJ; Kim AC; Eilertson B; Derti S; Jenkins SG; Levi MH; Weinstein MP; Tang YW; Hong T; Juretschko S; Hoffman KL; Walsh TJ; Westblade LF; Uhlemann AC; Kreiswirth BN Clin Infect Dis; 2022 Dec; 75(12):2066-2075. PubMed ID: 35522019 [TBL] [Abstract][Full Text] [Related]
14. Activity of Ceftazidime-Avibactam Alone and in Combination with Ertapenem, Fosfomycin, and Tigecycline Against Carbapenemase-Producing Ojdana D; Gutowska A; Sacha P; Majewski P; Wieczorek P; Tryniszewska E Microb Drug Resist; 2019 Nov; 25(9):1357-1364. PubMed ID: 31295055 [TBL] [Abstract][Full Text] [Related]
15. Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam. Papadimitriou-Olivgeris M; Bartzavali C; Lambropoulou A; Solomou A; Tsiata E; Anastassiou ED; Fligou F; Marangos M; Spiliopoulou I; Christofidou M J Antimicrob Chemother; 2019 Jul; 74(7):2051-2054. PubMed ID: 31002313 [TBL] [Abstract][Full Text] [Related]
16. Mechanistic Insights to Combating NDM- and CTX-M-Coproducing Klebsiella pneumoniae by Targeting Cell Wall Synthesis and Outer Membrane Integrity. Smith NM; Boissonneault KR; Chen L; Petraitis V; Petraitiene R; Tao X; Zhou J; Lang Y; Kavaliauskas P; Bulman ZP; Holden PN; Cha R; Bulitta JB; Kreiswirth BN; Walsh TJ; Tsuji BT Antimicrob Agents Chemother; 2022 Sep; 66(9):e0052722. PubMed ID: 35924913 [TBL] [Abstract][Full Text] [Related]
17. Sequential Treatment Failure With Aztreonam-Ceftazidime-Avibactam Followed by Cefiderocol Due to Preexisting and Acquired Mechanisms in a New Delhi Metallo-β-lactamase-Producing Escherichia coli Causing Fatal Bloodstream Infection. Senchyna F; Murugesan K; Rotunno W; Nadimpalli SS; Deresinski S; Banaei N Clin Infect Dis; 2024 Jun; 78(6):1425-1428. PubMed ID: 38289725 [TBL] [Abstract][Full Text] [Related]
19. Aztreonam, Ceftazidime/Avibactam, and Colistin Combination for the Management of Carbapenemase-Producing Shah PJ; Tran T; Emelogu F; Tariq F J Pharm Pract; 2021 Aug; 34(4):653-657. PubMed ID: 31698984 [TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo activity of ceftazidime/avibactam and aztreonam alone or in combination against mcr-9, serine- and metallo-β-lactamases-co-producing carbapenem-resistant Enterobacter cloacae complex. Li W; Zhang J; Fu Y; Wang J; Liu L; Long W; Yu K; Li X; Wei C; Liang X; Wang J; Li C; Zhang X Eur J Clin Microbiol Infect Dis; 2024 Jul; 43(7):1309-1318. PubMed ID: 38700663 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]